| Description | MCL0129, a selective and non-peptidergic melanocortin 4 (MC4) receptor antagonist, is a potential treatment for cachexia. |
| Synonyms | MCL-0129, MCL 0129 |
| molecular weight | 546.76 |
| Molecular formula | C34H47FN4O |
| CAS | 768357-45-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Foster AC, Chen C, Markison S, Marks DL. MC4 receptor antagonists: a potential treatment for cachexia. IDrugs. 2005 Apr;8(4):314-9. Review. PubMed PMID: 15800806. 2. Shimazaki T, Chaki S. Anxiolytic-like effect of a selective and non-peptidergic melanocortin 4 receptor antagonist, MCL0129, in a social interaction test. Pharmacol Biochem Behav. 2005 Mar;80(3):395-400. PubMed PMID: 15740781. 3. Chaki S, Hirota S, Funakoshi T, Suzuki Y, Suetake S, Okubo T, Ishii T, Nakazato A, Okuyama S. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynap hthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor. J Pharmacol Exp Ther. 2003 Feb;304(2):818-26. PubMed PMID: 12538838. |